Hyperfine Announces NEURO PMR Study Results, Portable MRI Shows Superiority
Hyperfine announced results from the NEURO PMR study, presented at the American Society of Neuroimaging annual meeting in San Juan, Puerto Rico on January 16. NEURO PMR is the first prospective, multi-center, real-world study to evaluate the clinical utility and patient experience of portable MRI compared to standard-of-care MRI in outpatient neurology clinics. Two sites-DENT Neurologic Institute and Texas Neurology-enrolled 125 patients with neurologic conditions commonly seen in the outpatient setting, including headache, dementia, multiple sclerosis follow-up, and tumor surveillance. Patients received brain imaging on both the portable Swoop system and a conventional high-field MRI, enabling direct modality comparisons. Portable MRI demonstrated 92% concordance with standard MRI in identifying the presence or absence of intracranial pathology during a blinded review by independent neuroradiologists. In unblinded paired image reviews incorporating clinical history, concordance increased to 98%, as assessed by a neurologist and neuroimager. Patients reported that they were four times more likely to choose it over standard MRI. Across all experience measures-including comfort, anxiety, claustrophobia, noise, and overall satisfaction-portable MRI was rated superior to standard MRI.
Trade with 70% Backtested Accuracy
Analyst Views on HYPR
About HYPR
About the author

VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million, with proceeds allocated for critical commercialization activities and manufacturing scale-up, thereby accelerating the market introduction of its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into MRI-level 3D volumetric models, enhancing the accuracy of heart assessments, which is expected to significantly improve hospitals' diagnostic capabilities and patient treatment outcomes.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby driving market adoption and revenue growth.
- Executive Appointment: VentriPoint appointed David Swetlow as Chief Financial Officer, who brings over 15 years of management experience in the medical technology sector, a move seen as crucial for advancing the company's commercial strategy to shorten sales cycles and establish sustainable revenue streams.

VentriPoint Diagnostics Secures $1 Million Funding to Advance Cardiac Imaging Technology
- Funding Expansion: VentriPoint Diagnostics increased its private placement from $500,000 to $1 million due to strong investor demand, with proceeds aimed at critical commercialization activities and scaling manufacturing to accelerate market entry for its cardiac imaging technology.
- Technological Innovation: The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy, significantly enhancing the precision of heart assessments and promising measurable economic returns for hospitals, thereby boosting its competitive edge in the healthcare market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models that leverage real-world data to demonstrate potential savings for healthcare providers through process improvements and optimized resource allocation, further enhancing its market appeal.
- Executive Appointment: The appointment of David Swetlow as CFO, who brings over 15 years of senior management experience in medical technology, is viewed as a key step in driving market adoption and revenue growth, underscoring the company's commitment to future development.






